Synthesis, biological and modeling studies of 1,3-di-n-propyl-2,4-dioxo-6- methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as adenosine receptor antagonists

Farmaco

Volumn 60, Issue 8, 2005, Pages 643-651

  Pastorin, G ^a   Bolcato, C ^a   Cacciari, B ^b   Kachler, S ^c   Klotz, K N ^c   Montopoli, C ^d   Moro, S ^d   Spalluto, G ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

Adenosine receptors; Antagonists; Cycloaddition; G protein coupled receptors; Xanthine

Indexed keywords

1,3 DIPROPYL 2,4 DIOXO 6 METHYL 8 (4 AMINOPHENYL) 1,2,3,4 TETRAHYDRO[1,2,4]TRIAZOLO[3,4 F]PURINE; 1,3 DIPROPYL 2,4 DIOXO 6 METHYL 8 (4 NITROPHENYL) 1,2,3,4 TETRAHYDRO[1,2,4]TRIAZOLO[3,4 F]PURINE; 1,3 DIPROPYL 2,4 DIOXO 6 METHYL 8 [4 (ACETYLAMINO)PHENYL] 1,2,3,4 TETRAHYDRO[1,2,4]TRIAZOLO[3,4 F]PURINE; 1,3 DIPROPYL 2,4 DIOXO 6 METHYL 8 [4 (BENZOYLAMINO)PHENYL] 1,2,3,4 TETRAHYDRO[1,2,4]TRIAZOLO[3,4 F]PURINE; 1,3 DIPROPYL 2,4 DIOXO 6 METHYL 8 [4 [(2 THIENYLCARBONYL)AMINO]PHENYL] 1,2,3,4 TETRAHYDRO[1,2,4]TRIAZOLO[3,4 F]PURINE; 1,3 DIPROPYL 2,4 DIOXO 6 METHYL 8 [4 [(4 BIPHENYLYL)AMINO]PHENYL] 1,2,3,4 TETRAHYDRO[1,2,4]TRIAZOLO[3,4 F]PURINE; 1,3 DIPROPYL 2,4 DIOXO 6 METHYL 8 [4 [(4 METHOXYPHENYLCARBONYL)AMINO] PHENYL] 1,2,3,4 TETRAHYDRO[1,2,4]TRIAZOLO[3,4 F]PURINE; 1,3 DIPROPYL 2,4 DIOXO 6 METHYL 8 [4 [(ADAMANTYLCARBONYL)AMINO]PHENYL] 1,2,3,4 TETRAHYDRO[1,2,4]TRIAZOLO[3,4 F]PURINE; 1,3 DIPROPYL 2,4 DIOXO 6 METHYL 8 [4 [(BUTANOYL)AMINO]PHENYL] 1,2,3,4 TETRAHYDRO[1,2,4]TRIAZOLO[3,4 F]PURINE; 1,3 DIPROPYL 2,4 DIOXO 6 METHYL 8 [4 [(DIPHENYLACETYL)AMINO]PHENYL] 1,2,3,4 TETRAHYDRO[1,2,4]TRIAZOLO[3,4 F]PURINE; 1,3 DIPROPYL 2,4 DIOXO 6 METHYL 8 [4 [(ESANOYL)AMINO]PHENYL] 1,2,3,4 TETRAHYDRO[1,2,4]TRIAZOLO[3,4 F]PURINE; 1,3 DIPROPYL 2,4 DIOXO 6 METHYL 8 [4 [(PHENYLACETYL)AMINO]PHENYL] 1,2,3,4 TETRAHYDRO[1,2,4]TRIAZOLO[3,4 F]PURINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; G PROTEIN COUPLED RECEPTOR; METHYL GROUP; PURINE DERIVATIVE; RECEPTOR SUBTYPE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

ACYLATION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; CHO CELL; CYCLOADDITION; DRUG POTENCY; DRUG SYNTHESIS; ELECTRICITY; HUMAN; HUMAN CELL; MOLECULAR MODEL; NONHUMAN;

BINDING SITES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; PURINES; RATS; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; RECEPTOR, ADENOSINE A2B; RECEPTOR, ADENOSINE A3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 23944446094     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.farmac.2005.04.012     Document Type: Article

References (58)

1. B.B. Fredholm, A.P. IJzerman, K.A. Jacobson, K.N. Klotz, and J. Linden International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors Pharmacol. Rev. 53 2001 527 552
2. K.A. Jacobson, and L.J.S. Knutsen P1 and P2 purine and pyrimidine receptor ligands Handbook of Experimental Pharmacology 2001 129 175 [151/1 (purinergic and pyrimidinergic Signalling I)]
3. D. van Calker, M. Mueller, and B. Hamprecht Adenosine regulates via two different type of receptors, the accumulation of cyclic AMP in cultured brain cells J. Neurochem. 33 1979 999 1005
4. C. Londos, D.M.F. Cooper, and J. Wolff Subclasses of external adenosine receptors Proc. Natl. Acad. Sci. USA 77 1980 2551 2554
5. J.W. Daly, P. Butts-Lamb, and W. Padgett Subclasses of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines Cell. Mol. Neurobiol. 3 1983 69 80
6. 3 Adenosine receptor ligands; history and perspectives Med. Res. Rev. 20 2000 103 128
7. K.A. Jacobson, and F. Suzuki Recent developments in selective agonists and antagonists acting at purine and pyrimidine receptors Drug Dev. Res. 39 1996 289 300
8. K.A. Jacobson, and A.M. Van Rhee Development of selective purinoceptor agonists and antagonists K.A. Jacobson M.F. Jarvis Purinergic Approaches Exp. Ther 1997 Wiley-Liss Publisher New York 101 128
9. W. Soudijn, I. Van Wijngaarden, and A.P. IJzerman Medicinal chemistry of adenosine receptor ligands Current Topic Med. Chem. 3 2003 355 367
10. 2A adenosine receptor antagonists Current Topic Med. Chem. 3 2003 403 411
11. 2B adenosine receptors J. Med. Chem. 43 2000 1165 1172
12. 2B-selective adenosine receptor antagonists J. Med. Chem. 45 2002 1500 1510
13. 3 adenosine receptor antagonists J. Med. Chem. 45 2002 3337 3344
14. 3 adenosine receptor antagonists J. Med. Chem. 45 2002 3440 3450
15. G. Pastorin, C. Bolcato, B. Cacciari, S. Kachler, K.N. Klotz, C. Montopoli, S. Moro, and G. Spalluto Synthesis, biological studies and molecular modeling investigation of 1,3-dimethyl-2,4-dioxo-6-methyl-8-(substituted)1,2,3, 4-tetrahydro [1,2,4] triazolo[3,4-f]purines as potential adenosine receptor antagonists., Il Farmaco 2005 (in press)
16. A.S. Shawali, and C. Parkanyi Hydrazidoyl halides in the synthesis of heterocycles J. Hetrocyl. Chem. 17 1980 833 854
17. A.S. Shawali Reaction of heterocyclic compounds with nitrilimines and their precursor Chem. Rev. 93 1993 2731 2777
18. 2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility J. Med. Chem. 45 2002 115 126
19. 2 affinity J. Med. Chem. 34 1991 1431 1435
20. 2-adenosine receptors J. Med. Chem. 28 1985 487 492
21. H. Maschler, B.A. Spicer, and S. Harry Xanthine derivatives, process for their preparation and their pharmaceutical uses, European Patent Appl. No 96363093,0 1990
22. A.M. Mosselhi, W. Pfeiderer, and X. Purines IV. Synthesis and properties of 8-nitro xanthine and its N-methyl derivatives J. Hetrocycl. Chem. 30 1993 1221 1228
23. G. Serchi, L. Sancio, and G. Bichi Ricerche sulle xantine. Nota 1. Benzil derivati della 1-3 dimetil xantina Il Farmaco Ed Sci. X 1955 733 741
24. A.F. Hagarty, M.P. Cashman, and F.L. Scott Synthesis of aliphatic hydrazonoyl bromides and kinetics of their conversion into hydrazides J. Chem. Soc. Perkin Trans. II 1972 1381 1386
25. A.S. Shawali, A.M. Mosselhi, and N.M. Tawfik A simple one-pot synthesis of novel [1,2,4]triazolo[3,4-f]purines J. Org. Chem. 66 2001 4055 4057
26. 6-phenylisopropyladenosine Naunyn Schmiedebergs Arch. Pharmacol. 313 1980 179 187
27. 2 receptors in rat brain tissue J. Pharmacol. Exp. Ther. 251 1989 888 893
28. 1-selective adenosine antagonist 8-cyclopentyl-1,3-dipropyl-xanthine to rat brain membranes Naunyn Schmiedebergs Arch. Pharmacol. 335 1987 59 63
29. 2a adenosine receptor Mol. Pharmacol. 48 1996 970 974
30. 3 adenosine receptor Mol. Pharmacol. 45 1994 978 982
31. K.N. Klotz, J. Hessling, J. Hegler, C. Owman, B. Kull, B.B. Fredholm, and M.J. Lohse Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells Naunyn Schmiedebergs Arch. Pharmacol. 357 1998 1 9
32. K.-N. Klotz, G. Cristalli, M. Grifantini, S. Vittori, and M.J. Lohse Photoaffinity labeling of A1 -adenosine receptors J. Biol. Chem. 260 1985 14659 14664
33. S. Moro, F. Deflorian, G. Pastorin, B. Cacciari, S.K. Kim, and K.A. Jacobson Demystifying the three dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modelling Chem. Commun. (Camb.) 2003 2949 2956
34. 3 adenosine receptor antagonist J. Med. Chem. 45 2002 3579 3582
35. 2B adenosine receptor subtypes: a molecular modeling investigation J. Med. Chem. 46 2003 4287 4296
36. 3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies J. Med. Chem. 47 2004 3580 3590
37. 3 adenosine receptor binding site: sterically constrained N6-(2-phenylethyl)adenosine derivatives as potent ligands Bioorg. Med. Chem. 12 2004 2021 2034
38. 3 adenosine receptors J. Biol. Chem. 269 1994 24692 24698
39. 3 adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives Mol. Pharmacol. 60 2001 1057 1063
40. 3 adenosine receptor J. Biol. Chem. 277 2002 19056 19063
41. 3-selective adenosine agonists J. Med. Chem. 37 1994 636 646
42. 3 adenosine receptor Mol. Pharmacol. 45 1994 1101 1111
43. A. van Bergen, P.J.M. van Galen, G.L. Stiles, and K.A. Jacobson A3 Receptors: Structure Activity Relationship and Molecular Modeling, ACS 206th National Meeting, Chicago, IL August 1993 [Abstract MEDI217]
44. J. Linden Calculating the dissociation constant of an unlabeled compound from the concentration required to displace radiolabel binding by 50% J. Cyclic Nucleotide Res. 8 1982 163 172
45. 50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
46. OpenMosix, http://www.openMosix.org.
47. Molecular Operating Environment (MOE 2003.02), Chemical Computing Group, Inc, 1255 University St., Suite 1600, Montreal, Quebec, Canada, H3B 3X3.
48. Spartan O2, Wavefuncion Inc., 18401 Von Karman Ave., Irvine, CA 92612 USA.
49. W.D. Cornell, P. Cieplak, C.I. Bayly, I.R. Gould, K.M. Merz, D.M. Ferguson, D.C. Spellmeyer, T. Fox, J.W. Caldwell, and P.A. Kollman A second generation force field for the simulation of proteins, nucleic acids and organic molecules J. Am. Chem. Soc. 117 1995 5179 5196
50. C.A. Baxter, C.W. Murray, D.E. Clark, D.R. Westhead, and M.D. Eldridge Flexible docking using tabu search and an empirical estimate of binding affinity. Proteins Struct. Funct. Genet. 33 1998 367 382
51. T.A. Halgren Merck molecular force field., I. basis, form, scope, parameterization, and performance of MMFF94 J. Comput. Chem. 17 1996 490 519
52. T.A. Halgren Merck molecular force field., II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions J. Comput. Chem. 17 1996 520 552
53. T.A. Halgren Merck molecular force field., III. Molecular geometries and vibrational frequencies for MMFF94 J. Comput. Chem. 17 1996 553 586
54. T.A. Halgren Merck molecular force field. IV. Conformational energies and geometries for MMFF94 J. Comput. Chem. 17 1996 587 615
55. T.A. Halgren, and R. Nachbar Merck molecular force field., V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules J. Comput. Chem. 17 1996 616 641
56. T.A. Halgren MMFF VI. MMFF94s Option for energy minimization studies J. Comput. Chem. 20 1999 720 729
57. T.A. Halgren MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries J. Comput. Chem. 20 1999 730 748
58. M.J. Lohse, K.-N. Klotz, J. Lindenborn-Fotinos, M. Reddington, U. Schwabe, and R.A. Olsson 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) - a selective high affinity antagonist radioligand for A1 adenosine receptors Naunyn-Schmiedeberg's Arch. Pharmacol. 336 1987 204 210